profit from every $100 of sales.
$0$100
NovoCure
$11.99+1.52% today
+1.1% in 1 year
1-year low $10.031-year high $19.99
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What NovoCure sold, what it kept, and what it did with the cash.
Sales went from $538 million in 2022 to $655 million in 2025, with -$136 million of profit last year.
SalesProfit
NovoCure vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| NovoCure | No profit yet | ||
 ResMed | 22.0× · Fair price | ||
 West Pharmaceutical Services | 58.3× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads NovoCure's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 538 | 509 | 605 | 655 | |
| 423 | 381 | 468 | 488 | |
| -90 | -233 | -170 | -154 | |
| -68 | -177 | -110 | -105 | |
| -93 | -207 | -169 | -136 | |
| -0.88 | -1.95 | -1.56 | -1.22 | |
| 78.6% | 74.8% | 77.3% | 74.5% | |
| -16.6% | -45.7% | -28.2% | -23.5% | |
| -17.2% | -40.6% | -27.9% | -20.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,192 | 1,146 | 1,241 | 804 |
| Cash | 115 | 241 | 164 | 94 |
| Total debt | 584 | 605 | 683 | 248 |
| Total liabilities | 750 | 784 | 881 | 464 |
| 441 | 362 | 360 | 340 | |
| 105 | 106 | 108 | 111 | |
| -6.0% | -15.4% | -9.1% | -16.0% | |
| -21.0% | -57.1% | -46.8% | -40.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 31 | -73 | -26 | -49 | |
| 21 | 27 | 43 | 27 | |
| 9 | -100 | -69 | -76 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 107 | 116 | 160 | 105 |
Valuation
- –
- –
- –
- 6.4×
- 2.1×
- –
- –
- -5.4%
- -9.7%
- 0.0%
Profitability
- 74.5%
- -23.5%
- -20.8%
- -23.7%
- -31.8%
- -14.9%
- -50.8%
- -22.0%
- -32.1%
- 34.0%
Growth
- +6.8%
- –
- −9.3%
- –
- +1.9%
Financial health
- –
- 0.71
- 29.8%
- -99.8×
- 2.90
- 2.70
- 0.86
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 14%of 958
Bottom 10%of 889
Bottom 36%of 890
Bottom 17%of 987
What analysts expect
- Average price target
- $33.50
- Range
- $20.00 – $47.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | -0.62 | -0.51 | −21.0% |
| Feb 26, 2026 | -0.22 | -0.41 | +46.3% |
| Oct 30, 2025 | -0.33 | -0.42 | +21.4% |
| Jul 24, 2025 | -0.36 | -0.39 | +7.7% |
| Apr 24, 2025 | -0.31 | -0.47 | +34.0% |
| Feb 27, 2025 | -0.61 | -0.34 | −79.4% |
| Oct 30, 2024 | -0.28 | -0.34 | +17.6% |
| Jul 25, 2024 | -0.31 | -0.40 | +22.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
26No pass
Benjamin Graham
34No pass
Philip Fisher
34No pass
Peter Lynch
33No pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
30No pass
Questions about NovoCure
Is NovoCure a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the NovoCure AI analysis
What does NovoCure do?
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. It is in Medical - Instruments & Supplies.
Does NovoCure pay a dividend?
No. NovoCure does not pay a dividend at the moment.
Is NovoCure stock halal?
Questionable. NovoCure sits in a grey zone: its cash and confirmed interest-bearing investments are 32% of its market value, between 30% and 33%. How we check
How has NovoCure stock done over the past year?
Up 1.1% over the past twelve months, to $11.99. It traded between $10.03 and $19.99 and is 40.0% below its high.
Who are NovoCure's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with NovoCure's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.